<- Go Home
Devyser Diagnostics AB (publ)
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.
Market Cap
SEK 1.3B
Volume
29.5K
Cash and Equivalents
SEK 77.5M
EBITDA
SEK 20.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 201.9M
Profit Margin
80.60%
52 Week High
SEK 159.60
52 Week Low
SEK 74.00
Dividend
N/A
Price / Book Value
3.63
Price / Earnings
-151.57
Price / Tangible Book Value
3.80
Enterprise Value
SEK 1.3B
Enterprise Value / EBITDA
38.26
Operating Income
SEK 11.6M
Return on Equity
2.39%
Return on Assets
1.54
Cash and Short Term Investments
SEK 77.5M
Debt
SEK 51.9M
Equity
SEK 354.3M
Revenue
SEK 250.5M
Unlevered FCF
-SEK 54.9M
Sector
Biotechnology
Category
N/A